Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Ragweed Sublingual Tablet (SCH 39641) in Adult Subjects With Ragweed-Induced Rhinoconjunctivitis
NCT00770315Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Sep 2009
- Primary completion
- May 2011
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of SQ SLIT-tablet in allergic rhinoconjunctivitis (ARC), sponsored by ALK-Abelló. Started Sep 2009; status: completed.
02
Drugs
SQ SLIT-tablet
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00770315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00770315.